AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC increased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 8.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 26,979 shares of the company’s stock after acquiring an additional 2,012 shares during the period. Exchange Traded Concepts LLC’s holdings in AstraZeneca were worth $1,768,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. AQR Capital Management LLC boosted its stake in shares of AstraZeneca by 112.4% during the 2nd quarter. AQR Capital Management LLC now owns 13,685 shares of the company’s stock worth $1,067,000 after acquiring an additional 7,241 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in AstraZeneca by 39.1% during the second quarter. The Manufacturers Life Insurance Company now owns 206,446 shares of the company’s stock worth $16,104,000 after purchasing an additional 58,039 shares in the last quarter. Mackenzie Financial Corp increased its position in shares of AstraZeneca by 9.3% in the second quarter. Mackenzie Financial Corp now owns 307,954 shares of the company’s stock valued at $24,017,000 after buying an additional 26,213 shares in the last quarter. Scientech Research LLC acquired a new position in shares of AstraZeneca during the 2nd quarter worth $407,000. Finally, Kathmere Capital Management LLC boosted its position in shares of AstraZeneca by 35.3% in the 2nd quarter. Kathmere Capital Management LLC now owns 5,501 shares of the company’s stock worth $429,000 after buying an additional 1,436 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Stock Performance

AstraZeneca stock opened at $69.06 on Monday. The company has a market cap of $214.16 billion, a price-to-earnings ratio of 33.04, a price-to-earnings-growth ratio of 1.13 and a beta of 0.46. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The stock’s 50-day moving average is $66.44 and its 200-day moving average is $74.17.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.03. The company had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.87 earnings per share. Equities analysts anticipate that AstraZeneca PLC will post 4.12 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on AZN. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.